Date: 2016-10-14
Type of information: R&D agreement
Compound: ACT017
Company: Acticor Biotech (France) Mediolanum farmaceutici (Italy)
Therapeutic area: Cardiovascular diseases - Cerebrovascular diseases
Type agreement: R&D development
Action mechanism: monoclonal antibody. ACT017 is a humanized Antibody Fragment (Fab) directed against platelet glycoprotein VI (GPVI). Evidence of antithrombotic efficacy of ACT017 and safety of inhibition of GPVI have been established both ex vivo and in vivo. The target is involved in the growth of the thrombus, but not in physiological hemostasis. This limits the bleeding risk associated with its inhibition. ACT017 is based on the results of researches conducted by, the founders: Dr. Martine Jandrot-Perrus and Dr Christian Gachet, in two INSERM units, and Professor Philippe Billiald at Paris-Sud University.
Disease: acute ischemic stroke
Details: * On October 14, 2016, Acticor Biotech and Mediolanum farmaceutici announced that they have entered into a research collaboration agreement for Acticor’s project ACT017, a humanized antibody Fragment (Fab). Under the terms of the agreement, Mediolanum will co-finance research and development of ACT017, currently in preclinical development as a potential next generation antithrombotic treatment for acute ischemic stroke. Under the terms of the agreement, Acticor received an undisclosed nonrefundable lump sum payment for the preclinical development of ACT017 and is eligible for additional payments to launch clinical development phases 1 and 2. Mediolanum will co-own the results of the collaboration and will acquire marketing rights over two main European countries.
Financial terms:
Latest news:
